WLBU2

WLBU2 is an engineered cationic antimicrobial peptide (eCAP) designed to overcome the sensitivity issues of natural antimicrobial peptides (AMPs) in various environments. WLBU2 exhibits rapid bactericidal activity and has a minimum inhibitory concentration (MIC) value of ≤ 10 μM against numerous Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, Klebsiella pneumoniae, Enterobacter aerogenes, Enterobacter cloacae, and Escherichia coli. It effectively prevents biofilm formation by Pseudomonas aeruginosa and retains its activity in mucus-rich, low pH, and high salt conditions, without adverse effects on human respiratory epithelial cells. Additionally, WLBU2 is applicable for studying cystic fibrosis (CF) and Pseudomonas aeruginosa infections.

C([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC=1C=2C(NC1)=CC=CC2)NC([C@@H](NC([C@H](CCCNC(=N)N)N)=O)CCCNC(=N)N)=O)=O)C(C)C)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)[C@@H](C)C)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC=3C=4C(NC3)=CC=CC4)C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(=N)N)C(O)=O)=O)CCCNC(=N)N)=O)C(C)C)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)C(C)C)=O)[C@H](C)C)=O)CCCNC(=N)N)=O)[C@@H](C)C)=O)C(C)C)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)[C@H](C)C)=O)C=5C=6C(NC5)=CC=CC6